2026. Endpoint Selection in Rare Disease Trials: Composite Measures and the Loss of Interpretability. Translational Medicine & Therapeutics Journal. 5, 2 (Feb. 2026), 10–18. DOI:https://doi.org/10.5281/zenodo.22649538.